Clene Inc. (CLNN)

Pharmaceutical Preparations · market cap $55M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Clene Inc. (CLNN) is a small-cap pharmaceutical company with a market cap of ~$82M developing CNM-Au8, a gold nanocrystal therapeutic, in Phase 3 for Relapsing Multiple Sclerosis and Phase 2 for ALS. The company has ~$5.9M cash, implying a runway of only ~3.9 months, net debt of $23.1M, and zero revenue, creating acute near-term financing pressure.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
CNMAu8	Phase 2	Amyotrophic Lateral Sclerosis
CNM-ZnAg	Phase 2	Covid19
gold nanocrystals	Phase 2	Multiple Sclerosis
CNM-Au8	Phase 3	Relapsing Multiple Sclerosis

Price & technical context

3-month

-34.1%

6-month

-17.8%

12-month

-33.3%

52-wk range

$3.28–$12.50

vs 50-day MA

-8.8%

vs 200-day MA

-25.9%

Realized vol

104.8%

Max drawdown

-73.8%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CLNN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.